Demographic features and travel-related characteristics of all pretravel consultations
| Characteristics | All travellers (n=1341) | |
| Sex | Male | 657 (49.0) |
| Female | 684 (51.0) | |
| Age | Median | 33 years |
| IQR | 26–46 years | |
| Range | 0–82 years | |
| <10 years | 58 (4.3) | |
| 10–17 years | 68 (5.1) | |
| 18–59 years | 1077 (80.3) | |
| ≥60 years | 138 (10.3) | |
| Nationality | Chile | 1129 (84.2) |
| Non-Chilean | 212 (15.8) | |
| Latin America | 87 (6.5) | |
| Europe | 75 (5.6) | |
| North America | 25 (1.9) | |
| Other | 25 (1.9) | |
| Travel reason | Leisure | 1021 (76.1) |
| Tourism | 893 (66.6) | |
| Backpacking | 154 (11.5) | |
| Adventure travel | 78 (5.8) | |
| Work related | 311 (23.2) | |
| Business | 267 (19.9) | |
| Study | 46 (3.4) | |
| Others | 72 (5.4) | |
| VFR | 64 (4.8) | |
| Pilgrimage | 8 (0.6) | |
| Travel duration | Median | 21 days |
| IQR | 93.1 days | |
| Range | 1 day-6 years | |
| 1–7 days | 208 (15.5) | |
| 8–14 days | 338 (25.3) | |
| 15–28 days | 495 (37.0) | |
| 29–90 days | 115 (8.6) | |
| >90 days | 182 (13.6) | |
| Time to departure | Median | 28 days |
| IQR | 14–49 days | |
| Range | 0–220 days | |
| 0–13 days | 311 (23.2) | |
| 14–27 days | 343 (25.6) | |
| ≥28 days | 666 (49.7) | |
| Destinations | America | 544 (40.6) |
| Asia | 477 (35.6) | |
| Africa | 352 (26.2) | |
| Oceania | 66 (4.9) | |
| Europe | 64 (4.8) | |
| Less developed regions* | 1284 (95.7) | |
| 1 region* visited | 984 (73.4) | |
| 2 regions* visited | 277 (20.7) | |
| ≥3 regions* visited | 80 (6.0) | |
| Infection risk | Dengue (tropical arboviruses) | 1261 (94.0) |
| Malaria | 926 (69.1) | |
| Yellow fever | 502 (37.4) | |
| Indicated vaccines | Hepatitis A | 1124 (83.8) |
| Yellow fever† | 771 (57.5) | |
| Visiting endemic region | 411 (30.6) | |
| Entry requirement | 373 (27.8) | |
| Waiver letter | 70 (5.2) | |
| Typhoid fever | 682 (50.9) | |
| Rabies | 382 (28.5) | |
| Measles | 280 (20.9) | |
| Polio | 103 (7.7) | |
| Japanese encephalitis | 86 (6.4) | |
| Meningococcal | 68 (5.1) | |
| Malaria prevention | Chemoprophylaxis | 375 (28.0) |
| Stand-by emergency treatment | 164 (12.2) | |
| Mosquito prevention only | 387 (28.9) |
Values represent number (%) of consultations, if not otherwise specified.
*According to United Nations classification.12
†Indication for vaccine or waiver letter.
VFR, visiting friends and relatives.